tiprankstipranks
Trending News
More News >
Zymeworks (ZYME)
:ZYME
US Market
Advertisement

Zymeworks (ZYME) Earnings Dates, Call Summary & Reports

Compare
548 Followers

Earnings Data

Report Date
Mar 11, 2026
Before Open (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-0.53
Last Year’s EPS
-0.31
Same Quarter Last Year
Based on 10 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 06, 2025|
% Change Since:
|
Earnings Call Sentiment|Positive
The earnings call presented a mix of strong revenue growth and promising clinical data that suggest a positive outlook for Zymeworks. However, the discontinuation of a key program and the decrease in cash reserves present challenges. The sentiment is largely buoyed by the revenue increase and positive clinical trial results.
Company Guidance
During the third quarter of 2025, Zymeworks reported significant financial and clinical progress. The company recognized a $25 million development milestone from its collaboration with Johnson & Johnson, contributing to a total revenue of $27.6 million, a substantial increase from $16 million in the same period of 2024. Operating expenses slightly decreased by 1% to $49.7 million, and the net loss narrowed to $19.6 million from $29.9 million the previous year. Clinically, Zymeworks made strides with its Phase I programs, dosing the first patient in the ZW251 trial and presenting promising initial data for ZW191, showing a 64% objective response rate in certain patient groups. The company also continued its share repurchase program, completing $22.7 million of the remaining $30 million, reflecting confidence in its long-term outlook. As of September 30, 2025, Zymeworks held $299.4 million in cash and equivalents, with expectations to fund operations into the second half of 2027.
Significant Revenue Growth
Total revenue for Q3 2025 was $27.6 million, up from $16 million in Q3 2024, primarily due to a $25 million milestone from J&J related to pasritamig's clinical progress.
Promising Clinical Data for ZW191
ZW191 showed encouraging Phase I data with a high objective response rate of 64% in certain doses and a favorable safety profile, supporting its potential as a best-in-class folate receptor alpha directed ADC.
Strong Financial Position
Despite a net loss of $19.6 million, the company maintains $299.4 million in cash and anticipates funding operations until the second half of 2027.
Progress in Partnered Programs
Milestone revenue recognition from partnerships and strong performance in partnered programs, such as the collaboration with J&J and trials with Jazz, highlight the strength of Zymeworks' collaborations.

Zymeworks (ZYME) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

ZYME Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 11, 2026
2025 (Q4)
-0.53 / -
-0.31
Nov 06, 2025
2025 (Q3)
-0.29 / -0.26
-0.3933.33% (+0.13)
Aug 07, 2025
2025 (Q2)
-0.48 / 0.03
-0.49106.12% (+0.52)
May 08, 2025
2025 (Q1)
-0.68 / -0.30
-0.4228.57% (+0.12)
Mar 05, 2025
2024 (Q4)
-0.10 / -0.31
-0.2-55.00% (-0.11)
Oct 31, 2024
2024 (Q3)
-0.40 / -0.39
-0.414.88% (+0.02)
Aug 01, 2024
2024 (Q2)
-0.42 / -0.49
-0.7635.53% (+0.27)
May 02, 2024
2024 (Q1)
-0.32 / -0.42
-0.37-13.51% (-0.05)
Mar 06, 2024
2023 (Q4)
-0.41 / -0.20
4.65-104.30% (-4.85)
Nov 07, 2023
2023 (Q3)
-0.47 / -0.41
-0.7243.06% (+0.31)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

ZYME Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 06, 2025
$17.90$16.46-8.04%
Aug 07, 2025
$12.16$12.02-1.15%
May 08, 2025
$11.32$11.30-0.18%
Mar 05, 2025
$13.18$12.13-7.97%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Zymeworks (ZYME) report earnings?
Zymeworks (ZYME) is schdueled to report earning on Mar 11, 2026, Before Open (Confirmed).
    What is Zymeworks (ZYME) earnings time?
    Zymeworks (ZYME) earnings time is at Mar 11, 2026, Before Open (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is ZYME EPS forecast?
          ZYME EPS forecast for the fiscal quarter 2025 (Q4) is -0.53.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis